Business Wire
15 Dec 2025, 13:00 UTC · 41w ago
Verdict
Headline takes no side. We score QNCX +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Quince Therapeutics has completed the final patient visit for its pivotal Phase 3 NEAT clinical trial of encapsulated dexamethasone sodium phosphate (eDSP).
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of ticker scores this week
The company announced the completion of the last patient visit in its pivotal Phase 3 clinical trial for its lead asset.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
−96.6%
Price is moving against the score
$29.00 vs $844.00 close before publication (Dec 12) · not market-adjusted
QNCX chart →
